The Medicinal Chemistry Core is a newly proposed CCSG Core. The Medicinal Chemistry Core Laboratory was developed to provide the needed expertise in the area of synthesis of small molecules, modified peptides and bioconjugates for biomedical research by the Cancer Center research community. Creation of this Core was in direct response to a clearly defined need for providing synthesis of chemical reagents needed for preclinical studies (not for clinical drug development). The guiding principle was that the Center was not attempting to establish a GMP chemical production facility, but a chemical synthesis core laboratory to provide reagent grade compounds for use in validation and proof-of-principle target discovery studies. To accomplish this, there are a large number of investigators within the Center who have a need for a Medicinal Chemistry Core to provide unique reagents. These reagents are needed both for the study of the role of specific molecular targets controlling the growth and survival of cancer cells, as well as for the development of related reagents for cancer treatment. From the 2002 inception of the Medicinal Chemistry Core, its mission has been to provide very specific unique reagents to allow proof of principle and general drug discovery studies and accelerate basic sciences studies. The main purpose of the Medicinal Chemistry Core is: (1) To design and synthesize bioactive molecules in the most cost effective manner possible. (2) To optimize methods of purification of bioactive molecules at high yield. (3) To provide NMR, Mass spectrometry, and HPLC analysis for characterization of new anticancer agents. (4) To provide investigators with custom synthesis of anticancer agents in amounts ranging from milligrams to grams. (5) To provide experience and intuition for identification and optimization of lead compounds as well as promising reagents. This application requests support for a resource which continues to fulfill an essential role for peer reviewed research within the SKCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-46
Application #
7726522
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
46
Fiscal Year
2008
Total Cost
$84,465
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wei, Ting; Najmi, Saman M; Liu, Hester et al. (2018) Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint. Cell Rep 23:404-414
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Wang, Yuxuan; Li, Lu; Douville, Christopher et al. (2018) Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med 10:
Walter, Vonn; Du, Ying; Danilova, Ludmila et al. (2018) MVisAGe Identifies Concordant and Discordant Genomic Alterations of Driver Genes in Squamous Tumors. Cancer Res 78:3375-3385
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Tie, Jeanne; Cohen, Joshua D; Wang, Yuxuan et al. (2018) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut :
Stein-O'Brien, Genevieve; Kagohara, Luciane T; Li, Sijia et al. (2018) Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Med 10:37
Dean, Lorraine T; Montgomery, Madeline C; Raifman, Julia et al. (2018) The Affordability of Providing Sexually Transmitted Disease Services at a Safety-net Clinic. Am J Prev Med 54:552-558
Bastos, Diogo A; Antonarakis, Emmanuel S (2018) AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Precis Cancer Med 1:
Lu, Dai-Yin; Yalçin, Hulya; Yalçin, Fatih et al. (2018) Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 121:1081-1089

Showing the most recent 10 out of 2393 publications